COMPARE · Data as of August 12, 2026
GENB vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. GENB scored 25.7, HALO scored 85.6 — HALO leads.
Compare another set
GENB
Generate Biomedicines, Inc.
25.7
$15.09 · $1.9B
fundamentals as of
Score gap
59.9
HALO leads
HALO
Halozyme Therapeutics, Inc.
85.6
$101.79 · $11.6B
fundamentals as of
The model, pillar by pillar (0–100 each)
GENB
stronger →← stronger
HALO
34
Qualityreturns · margins · balance sheet
96
100
Growthrevenue & earnings expansion
100
2
Valuevaluation vs sector peers
65
HALO is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
GENB
HALO
-$246mF
FCF
$806mC+
+55.9%A
Rev
+41.2%A
0.14B+
D/E
—
73.1xD
P/S
—
—
PEG
0.80A-
—
P/E
30.1xB
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
GENB
HALO
—
Price vs fair valuelower is cheaper
42% below
—
Growth the price implies10-yr FCF · lower = less priced in
~-1%/yr
—
1-yr DCF upside
+37%
—
5-yr DCF upside
+73%
—
10-yr DCF upside
+143%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
GENB
Why this score
- Short track record
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
GENBGenerate Biomedicines, Inc.
Why now
Biotechnology · market cap $1.9b. 17% off the 52-week high of $18.18. Revenue growing +56% — in hypergrowth territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $25.60 (implying +70% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $11.6b. Trading near 52-week high of $104.78 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. PEG 0.80 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -2% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where GENB and HALO diverge
On the headline score the gap is 59.9 points in favour of HALO. The widest single difference is Value, where HALO leads by 63.2 points.
- ValueGENB 2.3 · HALO 65.5HALO +63.2
- QualityGENB 33.9 · HALO 95.7HALO +61.8
- GrowthGENB 100.0 · HALO 100.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.